What is the appropriate management for an adult female who developed a diffuse pruritic rash two weeks after completing cycle 6 of 5‑fluorouracil (5‑FU) and liposomal irinotecan chemotherapy?

Management of Diffuse Pruritic Rash After 5-FU and Liposomal Irinotecan

This is most likely a chemotherapy-induced dermatologic toxicity requiring immediate assessment of severity, continuation of chemotherapy with symptomatic management for mild-to-moderate cases, and treatment interruption only if the rash becomes intolerable or reaches grade 3 severity. 1

Immediate Diagnostic Considerations

Before initiating treatment, you must determine:

• Timing correlation: The 2-week delay after cycle 6 suggests a delayed hypersensitivity reaction rather than immediate drug allergy, which is consistent with chemotherapy-induced dermatologic toxicity patterns 1
• Rash characteristics: Document whether lesions are papulopustular (acneiform), maculopapular, or urticarial, as this guides specific management 1, 2
• Severity grading using CTCAE v5.0: Grade 1 (mild/localized), Grade 2 (intense/widespread/intermittent limiting instrumental ADLs), or Grade ≥3 (constant/limiting self-care ADLs or sleep) 1
• Rule out drug hypersensitivity to supportive medications: Consider that antiemetics (granisetron, ondansetron), corticosteroids, or other supportive agents—not the chemotherapy itself—may be the culprit 2

Critical pitfall: Do not automatically assume the chemotherapy agents caused the rash. In documented cases, supportive medications like granisetron caused generalized urticaria during the seventh chemotherapy course, and corticosteroid class allergies caused maculopapular rashes after first treatments 2

Management Algorithm Based on Severity

Grade 1 (Mild or Localized Pruritus)

• Continue chemotherapy at current dose and monitor for progression 1
• Apply topical moderate-to-high-potency corticosteroids (mometasone furoate 0.1% ointment or betamethasone valerate 0.1% ointment) to affected areas 1
• Consider topical antipruritic agents containing menthol 0.5% for additional relief 1
• Reassess after 2 weeks; if worsening or no improvement, escalate to Grade 2 management 1

Grade 2 (Intense/Widespread Pruritus, Intermittent)

• Continue chemotherapy at current dose while treating symptoms 1
• Initiate oral antihistamines: Use second-generation non-sedating agents (loratadine 10 mg daily) for daytime, or first-generation sedating agents (diphenhydramine 25-50 mg or hydroxyzine 25-50 mg) for nighttime pruritus 1
• Alternative or adjunctive therapy: GABA agonists such as pregabalin (25-150 mg daily) or gabapentin (900-3600 mg daily) can provide relief by reducing peripheral and central itch mediators 1
• Continue topical moderate-to-high-potency corticosteroids 1
• Reassess after 2 weeks; if no improvement, proceed to Grade 3 management 1

Grade ≥3 or Intolerable Grade 2

• Interrupt chemotherapy until symptoms return to Grade 0-1 1
• Continue aggressive symptomatic treatment with topical corticosteroids, oral antihistamines, and GABA agonists 1
• Reassess after 2 weeks; if reactions worsen or fail to improve, discontinuation per protocol may be necessary 1

Addressing Concomitant Skin Manifestations

If papulopustular (acneiform) rash accompanies pruritus—which is common with certain chemotherapy agents—treating the underlying rash will decrease pruritic symptoms 1. This requires:

• Oral antibiotics for 6 weeks: doxycycline 100 mg twice daily, minocycline 50 mg twice daily, or oxytetracycline 500 mg twice daily 1
• Topical low-to-moderate potency corticosteroids 1

Investigating Alternative Causes

Perform skin testing if the clinical picture suggests drug hypersensitivity rather than direct chemotherapy toxicity 2:

• Test antiemetics (granisetron, ondansetron, alizapride) 2
• Test corticosteroids used for premedication, checking for class-specific allergies 2
• Test any other supportive medications introduced around the time of rash onset 2

Skin testing allowed continuation of effective chemotherapy in documented cases once the responsible non-chemotherapy agent was identified and substituted 2.

Supportive Skin Care Measures

• Prevent and treat dry skin: Apply adequate moisturizers, as pruritus may occur secondary to xerosis 1
• Use lotions containing urea or polidocanol to soothe pruritus 1
• Avoid friction, heat exposure, and harsh soaps that exacerbate symptoms 1

Monitoring for Psychological Impact

Severe pruritus can lead to debilitating psychological distress, behavioral/adjustment disorders, and withdrawal from social life and work 1. Document pruritus intensity using visual analog or numeric rating scales, and assess impact on quality of life at each visit 1.

When to Escalate Care

• Obtain bacterial/viral/fungal cultures if signs of superinfection develop (increased warmth, purulent drainage, worsening erythema) 1
• Consider systemic corticosteroids (prednisone 0.5-1 mg/kg for 7 days) for severe, refractory cases with extensive skin involvement 1
• Dermatology consultation is warranted if the rash pattern is atypical, if standard management fails, or if considering isotretinoin (20-30 mg/day) for severe papulopustular eruptions 1

Key Takeaway

The appearance of pruritus is often associated with other skin alterations, and treatment of the concomitant rash can decrease pruritic symptoms 1. Most importantly, do not reflexively discontinue effective chemotherapy without first investigating whether supportive medications—rather than the chemotherapy itself—are responsible for the reaction 2.